Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt N/A
OTCPK:CZMWF's Cash-to-Debt is ranked higher than
74% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. OTCPK:CZMWF: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:CZMWF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28  Med: 10.33 Max: N/A
Current: N/A
Equity-to-Asset 0.64
OTCPK:CZMWF's Equity-to-Asset is ranked higher than
59% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. OTCPK:CZMWF: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:CZMWF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.63  Med: 0.68 Max: 0.72
Current: 0.64
0.63
0.72
Interest Coverage 80.49
OTCPK:CZMWF's Interest Coverage is ranked higher than
50% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. OTCPK:CZMWF: 80.49 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:CZMWF' s Interest Coverage Range Over the Past 10 Years
Min: 11.01  Med: 17.47 Max: 86.54
Current: 80.49
11.01
86.54
WACC vs ROIC
4.32%
14.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 15.04
OTCPK:CZMWF's Operating Margin % is ranked higher than
82% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. OTCPK:CZMWF: 15.04 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:CZMWF' s Operating Margin % Range Over the Past 10 Years
Min: 11.37  Med: 13.05 Max: 14.63
Current: 15.04
11.37
14.63
Net Margin % 10.17
OTCPK:CZMWF's Net Margin % is ranked higher than
82% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. OTCPK:CZMWF: 10.17 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:CZMWF' s Net Margin % Range Over the Past 10 Years
Min: 5.99  Med: 8.76 Max: 10.16
Current: 10.17
5.99
10.16
ROE % 14.45
OTCPK:CZMWF's ROE % is ranked higher than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. OTCPK:CZMWF: 14.45 )
Ranked among companies with meaningful ROE % only.
OTCPK:CZMWF' s ROE % Range Over the Past 10 Years
Min: 8.48  Med: 11.34 Max: 13.81
Current: 14.45
8.48
13.81
ROA % 9.46
OTCPK:CZMWF's ROA % is ranked higher than
83% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. OTCPK:CZMWF: 9.46 )
Ranked among companies with meaningful ROA % only.
OTCPK:CZMWF' s ROA % Range Over the Past 10 Years
Min: 5.72  Med: 7.84 Max: 9.47
Current: 9.46
5.72
9.47
ROC (Joel Greenblatt) % 26.19
OTCPK:CZMWF's ROC (Joel Greenblatt) % is ranked higher than
69% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. OTCPK:CZMWF: 26.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:CZMWF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.96  Med: 40.08 Max: 61.33
Current: 26.19
17.96
61.33
3-Year Revenue Growth Rate 6.30
OTCPK:CZMWF's 3-Year Revenue Growth Rate is ranked higher than
58% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. OTCPK:CZMWF: 6.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:CZMWF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.1  Med: 6.3 Max: 10.4
Current: 6.3
-13.1
10.4
3-Year EBITDA Growth Rate -0.80
OTCPK:CZMWF's 3-Year EBITDA Growth Rate is ranked lower than
54% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. OTCPK:CZMWF: -0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:CZMWF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -5.6  Med: 1.9 Max: 15.3
Current: -0.8
-5.6
15.3
3-Year EPS without NRI Growth Rate 2.30
OTCPK:CZMWF's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. OTCPK:CZMWF: 2.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:CZMWF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.9  Med: 3.9 Max: 18.4
Current: 2.3
-8.9
18.4
GuruFocus has detected 4 Warning Signs with Carl Zeiss Meditec AG $OTCPK:CZMWF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:CZMWF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CZMWF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:VWR, NAS:CPHD, NAS:BRKR, NAS:PRAH, NAS:EXAS, NAS:PRXL, OTCPK:SWTUY, NYSE:CRL, NYSE:ALR, NAS:ICLR, NAS:NEOG, NAS:INCR, NAS:AXDX, NAS:MEDP, NAS:FMI, NAS:VREX, NAS:MYGN, NAS:GHDX, NAS:ABAX, NAS:KANG » details
Traded in other countries:AFX.Germany, AFX.Switzerland, 0DHC.UK,
Headquarter Location:Germany
Carl Zeiss Meditec AG offers end-to-end solutions for the diagnosis and treatment of ophthalmic diseases, including implants and consumables. It provides visualization solutions in microsurgery. It offers its solutions to physicians and hospitals.

Carl Zeiss Meditec AG was incorporated in 1977. The Company offers complete solutions to diagnose and treat opthalmic diseases. It provides visualization solutions in microsurgery. It offers its solutions to physicians and hospitals. The Company operates in two main areas; Ophthalmology and Microsurgery. It offers a comprehensive portfolio of products and services that enable eye care professionals to meet the demands of an increasingly challenging healthcare environment. Ophthalmic equipment and systems offered by the Company are used for diagnosis, progress control, treatment and follow-up treatment of different ophthalmic syndromes It provides connectivity solutions to help increase efficiency and productivity with electronic workflow. The Company also offers clinical applications training and a broad range of service and support options. The products of Company include Surgical Microscopes, Intraoperative Fluorescence, Loupes, among others used in neurosurgery, spine surgery and others. These products are mainly used as supporting equipment for the removal of tumors as well as the treatment of vascular diseases and functional disorders. The Company's customers are physicians in various fields and hospitals. The Company operates under special government regulations while selling, manufacturing and launching products in the market.

Ratios

vs
industry
vs
history
PE Ratio 30.55
CZMWF's PE Ratio is ranked higher than
54% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. CZMWF: 30.55 )
Ranked among companies with meaningful PE Ratio only.
CZMWF' s PE Ratio Range Over the Past 10 Years
Min: 8.77  Med: 21.63 Max: 39.07
Current: 30.55
8.77
39.07
Forward PE Ratio 30.67
CZMWF's Forward PE Ratio is ranked lower than
70% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. CZMWF: 30.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.55
CZMWF's PE Ratio without NRI is ranked higher than
56% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. CZMWF: 30.55 )
Ranked among companies with meaningful PE Ratio without NRI only.
CZMWF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.77  Med: 21.63 Max: 39.07
Current: 30.55
8.77
39.07
Price-to-Owner-Earnings 31.53
CZMWF's Price-to-Owner-Earnings is ranked lower than
56% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. CZMWF: 31.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CZMWF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 23.6  Med: 61.58 Max: 307.56
Current: 31.53
23.6
307.56
PB Ratio 4.30
CZMWF's PB Ratio is ranked lower than
55% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. CZMWF: 4.30 )
Ranked among companies with meaningful PB Ratio only.
CZMWF' s PB Ratio Range Over the Past 10 Years
Min: 1.53  Med: 2.55 Max: 3.85
Current: 4.3
1.53
3.85
PS Ratio 3.12
CZMWF's PS Ratio is ranked higher than
57% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. CZMWF: 3.12 )
Ranked among companies with meaningful PS Ratio only.
CZMWF' s PS Ratio Range Over the Past 10 Years
Min: 1.23  Med: 1.94 Max: 3.12
Current: 3.12
1.23
3.12
Price-to-Free-Cash-Flow 42.72
CZMWF's Price-to-Free-Cash-Flow is ranked lower than
70% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. CZMWF: 42.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CZMWF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.19  Med: 32.39 Max: 118.66
Current: 42.72
11.19
118.66
Price-to-Operating-Cash-Flow 33.12
CZMWF's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. CZMWF: 33.12 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CZMWF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.09  Med: 26 Max: 62.82
Current: 33.12
9.09
62.82
EV-to-EBIT 20.72
CZMWF's EV-to-EBIT is ranked higher than
89% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. CZMWF: 20.72 )
Ranked among companies with meaningful EV-to-EBIT only.
CZMWF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.1  Med: 13.5 Max: 25
Current: 20.72
7.1
25
EV-to-EBITDA 18.92
CZMWF's EV-to-EBITDA is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. CZMWF: 18.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
CZMWF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 11.75 Max: 21.7
Current: 18.92
5.7
21.7
PEG Ratio 16.11
CZMWF's PEG Ratio is ranked lower than
95% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. CZMWF: 16.11 )
Ranked among companies with meaningful PEG Ratio only.
CZMWF' s PEG Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.72 Max: 217.06
Current: 16.11
0.74
217.06
Days Inventory 146.55
CZMWF's Days Inventory is ranked lower than
73% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. CZMWF: 146.55 )
Ranked among companies with meaningful Days Inventory only.
CZMWF' s Days Inventory Range Over the Past 10 Years
Min: 104.84  Med: 129.46 Max: 142.65
Current: 146.55
104.84
142.65
Days Sales Outstanding 82.34
CZMWF's Days Sales Outstanding is ranked lower than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. CZMWF: 82.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
CZMWF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.25  Med: 66.55 Max: 85.53
Current: 82.34
57.25
85.53
Days Payable 62.17
CZMWF's Days Payable is ranked higher than
57% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. CZMWF: 62.17 )
Ranked among companies with meaningful Days Payable only.
CZMWF' s Days Payable Range Over the Past 10 Years
Min: 28.98  Med: 40.99 Max: 62.07
Current: 62.17
28.98
62.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.98
CZMWF's Dividend Yield % is ranked higher than
52% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. CZMWF: 0.98 )
Ranked among companies with meaningful Dividend Yield % only.
CZMWF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.9  Med: 1.59 Max: 4.84
Current: 0.98
0.9
4.84
Dividend Payout Ratio 0.28
CZMWF's Dividend Payout Ratio is ranked lower than
53% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. CZMWF: 0.28 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CZMWF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.34 Max: 0.52
Current: 0.28
0.27
0.52
3-Year Dividend Growth Rate -1.70
CZMWF's 3-Year Dividend Growth Rate is ranked lower than
86% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. CZMWF: -1.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CZMWF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.7 Max: 30.5
Current: -1.7
0
30.5
Forward Dividend Yield % 1.01
CZMWF's Forward Dividend Yield % is ranked lower than
54% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. CZMWF: 1.01 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.67
CZMWF's 5-Year Yield-on-Cost % is ranked higher than
59% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. CZMWF: 1.67 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CZMWF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 2.7 Max: 8.23
Current: 1.67
0
8.23

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 5.92
CZMWF's Price-to-Tangible-Book is ranked lower than
52% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. CZMWF: 5.92 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CZMWF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.21  Med: 3.29 Max: 5.31
Current: 5.92
2.21
5.31
Price-to-Intrinsic-Value-Projected-FCF 9.01
CZMWF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. CZMWF: 9.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CZMWF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.11 Max: 7.48
Current: 9.01
1.14
7.48
Price-to-Median-PS-Value 1.60
CZMWF's Price-to-Median-PS-Value is ranked lower than
79% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CZMWF: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CZMWF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 0.97 Max: 1.99
Current: 1.6
0.72
1.99
Earnings Yield (Greenblatt) % 4.83
CZMWF's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. CZMWF: 4.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CZMWF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 7.4 Max: 14.1
Current: 4.83
4
14.1
Forward Rate of Return (Yacktman) % 2.16
CZMWF's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. CZMWF: 2.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CZMWF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.4  Med: 5.6 Max: 27.4
Current: 2.16
0.4
27.4

More Statistics

Revenue (TTM) (Mil) $1,220
EPS (TTM) $ 1.52
Beta0.34
Short Percentage of Float0.00%
52-Week Range $32.40 - 44.40
Shares Outstanding (Mil)81.31

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 1,234 1,320
EPS ($) 1.45 1.59
EPS without NRI ($) 1.45 1.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CZMWF

Headlines

Articles On GuruFocus.com
Royce International Premier Fund Semiannual Letter Sep 19 2016 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)